<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03097068</url>
  </required_header>
  <id_info>
    <org_study_id>ML39638</org_study_id>
    <nct_id>NCT03097068</nct_id>
  </id_info>
  <brief_title>Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis</brief_title>
  <official_title>Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Louis C. Glazer, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michigan State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vitreo-Retinal Associates, Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocol will measure a number of cytokines in addition to vascular endothelial growth
      factor in response to 0.3mg Lucentis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lucentis injections are the current standard of care for diabetic macular edema. The only
      deviation from the standard of care in the current protocol is an aqueous tap before the
      first Lucentis injection and the fourth Lucentis injection for diabetic macular edema.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2017</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>vascular endothelial growth factor levels</measure>
    <time_frame>One year</time_frame>
    <description>In aqueous</description>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis</intervention_name>
    <description>0.3mg Lucetnis</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of diabetes mellitus

          -  Best corrected visual acuity 20/32 - 20/320

          -  Diabetic macular edema involving the center of the macula

          -  Optical coherence tomography central subfield thickness of at least 250 microns

        Exclusion Criteria:

          -  History of anti-vascular endothelial growth factor treatment in the past 12 months

          -  Any diabetic macular edema treatment in the past 4 months

          -  Heart attack, stroke, transient ischemic attack or acute congestive heart failure
             within 4 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vitreo-Retinal Associates</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis C. Glazer, M.D.</last_name>
      <phone>616-285-1200</phone>
      <email>research@vrapc.com</email>
    </contact>
    <investigator>
      <last_name>Louis C. Glazer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vitreo-Retinal Associates, Michigan</investigator_affiliation>
    <investigator_full_name>Louis C. Glazer, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

